AstraZenecaThe National Institute of Allergy and Infectious Diseases (NIAID) has announced concerns with data from AstraZeneca’s COVID-19 vaccine trial.

NIAID, a wing of the National Institutes of Health (NIH), said in a statement today that it was concerned after information released by the company surrounding the clinical trial for its AZD1222 vaccine may be outdated. In turn, that may have provided an incomplete view of the efficacy data, NIAID said.

Get the full story at our sister site, Drug Discovery & Development.